Share Twitter LinkedIn Facebook Email Byoung Chul Cho, M.D., Yonsei Cancer Center discusses NSCLC With M7824 Second Line Therapy. At ESMO Oncology Conference – Munich, Germany On October 19, 2018.
Updates in Head and Neck Cancer [2023] Interview – Shirin Attarian, MD – MOASC Head and Neck 2 Mins Read
